News | Site Map | E-reporting
  Home Corporate Profile Business Divisions Products Careers Contacts Feedback
    
 
 

At the outset I take this opportunity to wish you and your familyaVery Happy and ProsperousNewYear!

I am happy to inform you that the Bombay Stock Exchange Ltd., (BSE) has re-listed our Shares, after giving effect to the Scheme of Reduction of Share Capital of the Company. You are also aware that w.e.f. 23.12.2006, the face value of the Shares has been reduced from Rs.10/- to Rs.5/- each. We have informed all of you as well as NSDL and CDSL about this change. Please note that our new ISIN No. is INE783B01029. After giving effect to the Scheme, the Issued and Paid-up Share Capital of the Company is Rs.10,64,06,425/- divided into 2,12,81,285 Equity Shares of Rs.5/- each. Needless to mention after Reduction of Share Capital the net worth of the Company has turned positive. The Company has made substantial profits during 05-06 and first-half of the Current Financial Year and has wiped-out accumulated losses.

You must have read the Audited Financial Results of the Company for the period ended 30.09.06. There is an all round growth in the turnover and profit of the company. As compared to last year, your Company has achieved a turnover of Rs.96.13 cr as compared to Rs.40.35 cr during the corresponding period of last year. Similarly, your Company has earned a net profit of Rs.6.21 cr during the said period. Coupled with net profit of Rs.9.68 cr earned by the company during financial year ended 31 March 06, the same has improved the financials of the Company to a considerable extent. This growth in turnover as well as profit is mainly due to company's continued efforts in strengthening the domestic as well as export marketing operations. During the above mentioned period there was substantial growth in the exports of the company. You will be glad to know that Pharma Industry is growing more than 18% for the first time in the last decade and your Company is no exception to this. This growth is expected to further increase. Even the third Quarter results of your company are also quite satisfactory. Considering the erformance of the Company in the current year and also plans for the next year, I am confident that we will be in a position to achieve our annual target.

Earning Per Share (E.P.S.) of the Company has increased from Rs.4.49 to on the annualized basis,during the current year.

The new plant which is being set up under Twilight Group at Baddi in the State of Himachal Pradesh will be commissioned as per our plan in April 2007. Once this plant is started increased capacity will leverage turnover and also higher profitability due to tax benefits. This will directly help the company to achieve better performance and profitability in the coming years. It is satisfying to note thatweare making progress as per our plan and investments made by the Company will prove to be extremely beneficial for the years ahead.

You will also be happy to note that your company successfully raised requisite amount of working capital funds from the Bankers of the Company at competitive rates. The funds thus raisedwill reduce the financial overheads and will give more certainty about achieving the targeted results.

The Audited Results in brief for the half year ended 30.09.2006 aregiven overleaf.

Onbehalf of theCompanyletme thank you for your unwavering support andgoodwishes.

Withwarmregards,


Gopal Ramourti
15th January, 2007th,
Pune
 
Home | Corporate Profile | Business Divisions | Products | Careers | Contacts | Feedback
Copyright © Twilight Litaka Pharma Ltd.